Available Until 8/22/2029

GLP-1 agonists and Neurodegenerative Disorders

ACPE Activity Number: 0204-0000-26-071-H01-P
Release Date: 08/22/2026
Expiration Date: 08/22/2029 
Activity Type: Knowledge-based
CE Credits:  0.25 contact hour, no partial credit
Activity Fee: Member – Free / Non-Member – Not Available 

Activity Overview 

This session will discuss the potential sites of action and benefits for GLP-1 agonists (GLP-1a) in the pathology of two neurodegenerative disorders, Alzheimer’s Disease (AD) and Parkinson’s Disease (PD)This session will also review the published and pending clinical literature of FDA approved GLP-1a use in AD and PD.